Reported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| CRESCENT BIOPHARMA, INC.CBIO · Entity 5255 | Director | June 02, 2026 | June 03, 2026 |
| Dianthus Therapeutics, Inc. /DE/DNTH · Entity 1813 | Director | May 21, 2026 | May 22, 2026 |
| Korsana Biosciences, Inc.KRSA · Entity 7698 | Director · See Remarks | September 08, 2026 | September 10, 2026 |
| TREVENA INCTRVN · Entity 85383 | SVP-Scientific Affairs & IR | February 28, 2018 | March 02, 2018 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
CRESCENT BIOPHARMA, INC.
Report date June 02, 2026 · Filed June 03, 2026
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $17.01 · Expires 2036-06-02 | Direct | 11,050 |
Reported balance
After 2026-06-02 transaction · row 1
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 1 · 2026-06-02 · Grant · Acquired 11,050 · Balance 11,050 F1: This option represents a right to purchase 11,050 of the Issuer's ordinary shares and vests in full on the earlier of (i) June 2, 2027 or (ii) the date of the Issuer's next annual meeting of shareholders, in each case, subject to the Reporting Person's continued service to the Issuer. |
Filing footnotes · ownership attribution and instrument terms
F1: This option represents a right to purchase 11,050 of the Issuer's ordinary shares and vests in full on the earlier of (i) June 2, 2027 or (ii) the date of the Issuer's next annual meeting of shareholders, in each case, subject to the Reporting Person's continued service to the Issuer.
Dianthus Therapeutics, Inc. /DE/
Report date May 21, 2026 · Filed May 22, 2026
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $89.63 · Expires 2036-05-21 | Direct | 6,090 |
Reported balance
After 2026-05-21 transaction · row 1
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 1 · 2026-05-21 · Grant · Acquired 6,090 · Balance 6,090 F1: The shares of common stock underlying this stock option award will vest in full on the date that is the earlier of (i) the first anniversary of the grant date or (ii) the Issuer's 2027 Annual Meeting of Stockholders, subject to the Reporting Person's continued service to the Issuer through the vesting date. |
Filing footnotes · ownership attribution and instrument terms
F1: The shares of common stock underlying this stock option award will vest in full on the date that is the earlier of (i) the first anniversary of the grant date or (ii) the Issuer's 2027 Annual Meeting of Stockholders, subject to the Reporting Person's continued service to the Issuer through the vesting date.
Korsana Biosciences, Inc.
Report date September 08, 2026 · Filed September 10, 2026
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 207,400 |
Reported balance
Holding disclosure · report date 2026-09-08 · row 1
Holding and transaction disclosures are not merged.
1 source rowRow 1 · Balance 207,400 F1: Effective as of September 8, 2026 (the "Effective Time"), (i) Cariboos Merger Sub Corp., a wholly owned subsidiary of Cyclerion Therapeutics, Inc. ("Cyclerion"), merged with and into Korsana Biosciences, Inc. ("Pre-Merger Korsana"), with Pre-Merger Korsana continuing as a wholly owned subsidiary of Cyclerion and the surviving corporation of the merger (the "First Merger"), and (ii) immediately thereafter, Pre-Merger Korsana merged with and into Cariboos Merger Sub II, LLC, a second wholly owned subsidiary of Cyclerion ("Second Merger Sub"), with Second Merger Sub being the surviving entity of the merger under the name Korsana Biosciences Operating Company, LLC (the "Second Merger" and, together with the First Merger, the "Merger"). At the Effective Time, Cyclerion changed its name to "Korsana Biosciences, Inc." (hereinafter, the "Issuer"). F2: Represents shares of the Issuer's common stock received by the Reporting Person in the Merger in exchange for the shares of Pre-Merger Korsana's common stock held by the Reporting Person prior to the Merger. Each share of Pre-Merger Korsana's restricted common stock held at the Effective Time was exchanged for 0.2074 restricted shares of the Issuer's common stock. Of these shares of common stock, 142,588 remain subject to forfeiture restrictions and vest in equal monthly installments through June 1, 2029, subject to the Reporting Person's continued service to the Issuer on each such vesting date. |
| Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $4.15 · Expires 2035-10-26 | Direct | Not disclosed |
Reported balance
Holding disclosure · report date 2026-09-08 · row 2
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 2 · Balance Not disclosed F1: Effective as of September 8, 2026 (the "Effective Time"), (i) Cariboos Merger Sub Corp., a wholly owned subsidiary of Cyclerion Therapeutics, Inc. ("Cyclerion"), merged with and into Korsana Biosciences, Inc. ("Pre-Merger Korsana"), with Pre-Merger Korsana continuing as a wholly owned subsidiary of Cyclerion and the surviving corporation of the merger (the "First Merger"), and (ii) immediately thereafter, Pre-Merger Korsana merged with and into Cariboos Merger Sub II, LLC, a second wholly owned subsidiary of Cyclerion ("Second Merger Sub"), with Second Merger Sub being the surviving entity of the merger under the name Korsana Biosciences Operating Company, LLC (the "Second Merger" and, together with the First Merger, the "Merger"). At the Effective Time, Cyclerion changed its name to "Korsana Biosciences, Inc." (hereinafter, the "Issuer"). F3: Represents options to purchase shares of the Issuer's common stock received by the Reporting Person in the Merger in exchange for options of Pre-Merger Korsana held by the Reporting Person prior to the Merger. This option vested as to 25% on June 1, 2026 and vests in equal monthly installments thereafter through June 1, 2029, subject to the Reporting Person's continued service to the Issuer on each such vesting date. |
| Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $8.06 · Expires 2036-06-29 | Direct | Not disclosed |
Reported balance
Holding disclosure · report date 2026-09-08 · row 3
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 3 · Balance Not disclosed F1: Effective as of September 8, 2026 (the "Effective Time"), (i) Cariboos Merger Sub Corp., a wholly owned subsidiary of Cyclerion Therapeutics, Inc. ("Cyclerion"), merged with and into Korsana Biosciences, Inc. ("Pre-Merger Korsana"), with Pre-Merger Korsana continuing as a wholly owned subsidiary of Cyclerion and the surviving corporation of the merger (the "First Merger"), and (ii) immediately thereafter, Pre-Merger Korsana merged with and into Cariboos Merger Sub II, LLC, a second wholly owned subsidiary of Cyclerion ("Second Merger Sub"), with Second Merger Sub being the surviving entity of the merger under the name Korsana Biosciences Operating Company, LLC (the "Second Merger" and, together with the First Merger, the "Merger"). At the Effective Time, Cyclerion changed its name to "Korsana Biosciences, Inc." (hereinafter, the "Issuer"). F4: Represents options to purchase shares of the Issuer's common stock received by the Reporting Person in the Merger in exchange for options of Pre-Merger Korsana held by the Reporting Person prior to the Merger. This option will vest as to 25% on June 18, 2027 and in equal monthly installments thereafter through June 18, 2030, subject to the Reporting Person's continued service to the Issuer on each such vesting date. |
Filing footnotes · ownership attribution and instrument terms
F1: Effective as of September 8, 2026 (the "Effective Time"), (i) Cariboos Merger Sub Corp., a wholly owned subsidiary of Cyclerion Therapeutics, Inc. ("Cyclerion"), merged with and into Korsana Biosciences, Inc. ("Pre-Merger Korsana"), with Pre-Merger Korsana continuing as a wholly owned subsidiary of Cyclerion and the surviving corporation of the merger (the "First Merger"), and (ii) immediately thereafter, Pre-Merger Korsana merged with and into Cariboos Merger Sub II, LLC, a second wholly owned subsidiary of Cyclerion ("Second Merger Sub"), with Second Merger Sub being the surviving entity of the merger under the name Korsana Biosciences Operating Company, LLC (the "Second Merger" and, together with the First Merger, the "Merger"). At the Effective Time, Cyclerion changed its name to "Korsana Biosciences, Inc." (hereinafter, the "Issuer").
F2: Represents shares of the Issuer's common stock received by the Reporting Person in the Merger in exchange for the shares of Pre-Merger Korsana's common stock held by the Reporting Person prior to the Merger. Each share of Pre-Merger Korsana's restricted common stock held at the Effective Time was exchanged for 0.2074 restricted shares of the Issuer's common stock. Of these shares of common stock, 142,588 remain subject to forfeiture restrictions and vest in equal monthly installments through June 1, 2029, subject to the Reporting Person's continued service to the Issuer on each such vesting date.
F3: Represents options to purchase shares of the Issuer's common stock received by the Reporting Person in the Merger in exchange for options of Pre-Merger Korsana held by the Reporting Person prior to the Merger. This option vested as to 25% on June 1, 2026 and vests in equal monthly installments thereafter through June 1, 2029, subject to the Reporting Person's continued service to the Issuer on each such vesting date.
F4: Represents options to purchase shares of the Issuer's common stock received by the Reporting Person in the Merger in exchange for options of Pre-Merger Korsana held by the Reporting Person prior to the Merger. This option will vest as to 25% on June 18, 2027 and in equal monthly installments thereafter through June 18, 2030, subject to the Reporting Person's continued service to the Issuer on each such vesting date.
TREVENA INC
Report date February 28, 2018 · Filed March 02, 2018
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Employee Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $1.79 · Expires 2028-02-28 | Direct | 75,000 |
Reported balance
After 2018-02-28 transaction · row 1
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 1 · 2018-02-28 · Grant · Acquired 75,000 · Balance 75,000 F1: The option shall vest and become exercisable with respect to one-sixteenth of the total number of shares subject to the option on a quarterly basis (every three months) from the Transaction Date listed above, subject to the reporting person's Continuous Service (as defined in the Trevena, Inc. 2013 Equity Incentive Plan, as amended) as of each such vesting date. |
| Employee Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $1.79 · Expires 2028-02-28 | Direct | 65,000 |
Reported balance
After 2018-02-28 transaction · row 2
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 2 · 2018-02-28 · Grant · Acquired 65,000 · Balance 65,000 F2: The option shall vest and become exercisable on an annual basis (every twelve months) from the Transaction Date listed above, with respect to one-half of the total number of shares subject to the option, in each case subject to the reporting person's Continuous Service (as defined in the 2013 Equity Incentive Plan, as amended) as of each such vesting date. |
Filing footnotes · ownership attribution and instrument terms
F1: The option shall vest and become exercisable with respect to one-sixteenth of the total number of shares subject to the option on a quarterly basis (every three months) from the Transaction Date listed above, subject to the reporting person's Continuous Service (as defined in the Trevena, Inc. 2013 Equity Incentive Plan, as amended) as of each such vesting date.
F2: The option shall vest and become exercisable on an annual basis (every twelve months) from the Transaction Date listed above, with respect to one-half of the total number of shares subject to the option, in each case subject to the reporting person's Continuous Service (as defined in the 2013 Equity Incentive Plan, as amended) as of each such vesting date.
Past disclosures · reporting ended (2)
No longer tracked through insider filings. These historical balances do not imply present ownership or a zero position.
Astria Therapeutics, Inc.
Report date January 23, 2026 · Filed January 23, 2026
Section 16 reporting ended · disclosed 2026-01-23. Current position is not established by this disclosure.
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 0 |
Reported balance
After 2026-01-23 transaction · row 1
1 source rowRow 1 · 2026-01-23 · Disposition to issuer · Disposed 263,321 · Balance 0 F1: Pursuant to an Agreement and Plan of Merger, dated as of October 14, 2025, by and among the Issuer, BioCryst Pharmaceuticals, Inc. ("BioCryst"), and Axel Merger Sub, Inc., a wholly-owned subsidiary of BioCryst, on January 23, 2026, Axel Merger Sub, Inc. merged with and into the Issuer, with the Issuer surviving and becoming a wholly-owned subsidiary of BioCryst (the "Merger"). At the effective time of the Merger (the "Effective Time"), each share of Issuer common stock, excluding shares held by the Issuer, BioCryst, or their wholly-owned subsidiaries or dissenting stockholders, that was issued and outstanding immediately prior to the Effective Time, was converted into the right to receive (i) 0.59 of a share of common stock of BioCryst and, if applicable, cash in lieu of fractional shares, and (ii) $8.55 in cash, without interest, subject to withholding taxes. |
| Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $12.24 | Direct | 0 |
Reported balance
After 2026-01-23 transaction · row 2
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 2 · 2026-01-23 · Disposition to issuer · Acquired 14,166 · Balance 0 F2: These numbers have been adjusted to reflect the 1-for-6 reverse stock split the Issuer effected on August 19, 2021. F3: At the Effective Time, each Issuer stock option for which the applicable exercise price was less than $13.00 (each, an "In-the-Money Option") that was outstanding immediately prior to the Effective Time became fully vested and exercisable and was canceled in exchange for the payment in cash equal to the product of (i) the total number of shares of common stock subject to such canceled In-the-Money Option immediately prior to the Effective Time and (ii) the excess of $13.00 over the exercise price per share subject to each such canceled In-the-Money Option, without interest. |
| Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $3.00 | Direct | 0 |
Reported balance
After 2026-01-23 transaction · row 3
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 3 · 2026-01-23 · Disposition to issuer · Acquired 8,333 · Balance 0 F3: At the Effective Time, each Issuer stock option for which the applicable exercise price was less than $13.00 (each, an "In-the-Money Option") that was outstanding immediately prior to the Effective Time became fully vested and exercisable and was canceled in exchange for the payment in cash equal to the product of (i) the total number of shares of common stock subject to such canceled In-the-Money Option immediately prior to the Effective Time and (ii) the excess of $13.00 over the exercise price per share subject to each such canceled In-the-Money Option, without interest. |
| Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $11.35 | Direct | 0 |
Reported balance
After 2026-01-23 transaction · row 4
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 4 · 2026-01-23 · Disposition to issuer · Acquired 14,100 · Balance 0 F3: At the Effective Time, each Issuer stock option for which the applicable exercise price was less than $13.00 (each, an "In-the-Money Option") that was outstanding immediately prior to the Effective Time became fully vested and exercisable and was canceled in exchange for the payment in cash equal to the product of (i) the total number of shares of common stock subject to such canceled In-the-Money Option immediately prior to the Effective Time and (ii) the excess of $13.00 over the exercise price per share subject to each such canceled In-the-Money Option, without interest. |
| Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $9.18 | Direct | 0 |
Reported balance
After 2026-01-23 transaction · row 5
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 5 · 2026-01-23 · Disposition to issuer · Acquired 14,100 · Balance 0 F3: At the Effective Time, each Issuer stock option for which the applicable exercise price was less than $13.00 (each, an "In-the-Money Option") that was outstanding immediately prior to the Effective Time became fully vested and exercisable and was canceled in exchange for the payment in cash equal to the product of (i) the total number of shares of common stock subject to such canceled In-the-Money Option immediately prior to the Effective Time and (ii) the excess of $13.00 over the exercise price per share subject to each such canceled In-the-Money Option, without interest. |
| Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $5.79 | Direct | 0 |
Reported balance
After 2026-01-23 transaction · row 6
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 6 · 2026-01-23 · Disposition to issuer · Acquired 26,550 · Balance 0 F3: At the Effective Time, each Issuer stock option for which the applicable exercise price was less than $13.00 (each, an "In-the-Money Option") that was outstanding immediately prior to the Effective Time became fully vested and exercisable and was canceled in exchange for the payment in cash equal to the product of (i) the total number of shares of common stock subject to such canceled In-the-Money Option immediately prior to the Effective Time and (ii) the excess of $13.00 over the exercise price per share subject to each such canceled In-the-Money Option, without interest. |
Filing footnotes · ownership attribution and instrument terms
F1: Pursuant to an Agreement and Plan of Merger, dated as of October 14, 2025, by and among the Issuer, BioCryst Pharmaceuticals, Inc. ("BioCryst"), and Axel Merger Sub, Inc., a wholly-owned subsidiary of BioCryst, on January 23, 2026, Axel Merger Sub, Inc. merged with and into the Issuer, with the Issuer surviving and becoming a wholly-owned subsidiary of BioCryst (the "Merger"). At the effective time of the Merger (the "Effective Time"), each share of Issuer common stock, excluding shares held by the Issuer, BioCryst, or their wholly-owned subsidiaries or dissenting stockholders, that was issued and outstanding immediately prior to the Effective Time, was converted into the right to receive (i) 0.59 of a share of common stock of BioCryst and, if applicable, cash in lieu of fractional shares, and (ii) $8.55 in cash, without interest, subject to withholding taxes.
F2: These numbers have been adjusted to reflect the 1-for-6 reverse stock split the Issuer effected on August 19, 2021.
F3: At the Effective Time, each Issuer stock option for which the applicable exercise price was less than $13.00 (each, an "In-the-Money Option") that was outstanding immediately prior to the Effective Time became fully vested and exercisable and was canceled in exchange for the payment in cash equal to the product of (i) the total number of shares of common stock subject to such canceled In-the-Money Option immediately prior to the Effective Time and (ii) the excess of $13.00 over the exercise price per share subject to each such canceled In-the-Money Option, without interest.
Viridian Therapeutics, Inc.\DE
Report date February 02, 2023 · Filed February 07, 2023 · Amendment
Section 16 reporting ended · disclosed 2023-02-07. Current position is not established by this disclosure.
Amendment: balances below belong to this corrected disclosure, not necessarily a complete replacement of earlier positions.
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 480,905 |
Last balance in matching sequence
After 2023-02-02 transaction · row 2
Source-order balances reconcile. Account continuity and personal attribution are not independently verified.
2 source rowsRow 1 · 2023-02-02 · Exercise / conversion · Acquired 50,000 · Balance 530,905 F1: Due to a broker error, the Form 4 filed by the Reporting Person on February 3, 2023 incorrectly reported the source of shares sold on February 2, 2023 pursuant to the Reporting Person's Rule 10b5-1 trading plan. This amendment reflects the exercise of stock options for 50,000 shares of common stock, which were the source of the shares sold. Row 2 · 2023-02-02 · Sale · Disposed 50,000 · Balance 480,905 F2: This transaction was executed pursuant to a Rule 10b5-1 trading plan in multiple trades at prices ranging from $36.1523 to $37.3689. The price reported above reflects the weighted average sales price. The reporting person hereby undertakes to provide upon request to the SEC staff, the Issuer or a security holder of the Issuer full information regarding the number of shares and prices at which the transaction was effected. |
| Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $0.15 · Expires 2030-09-23 | Direct | 239,205 |
Reported balance
After 2023-02-02 transaction · row 3
Amendment: may correct only part of an earlier disclosure.
1 source rowRow 3 · 2023-02-02 · Exercise / conversion · Disposed 50,000 · Balance 239,205 F3: The option vested 25% on September 23, 2021 and then in equal monthly installments over the following 3 years, subject to the Reporting Person's continued service to Issuer through each vesting date. |
Filing footnotes · ownership attribution and instrument terms
F1: Due to a broker error, the Form 4 filed by the Reporting Person on February 3, 2023 incorrectly reported the source of shares sold on February 2, 2023 pursuant to the Reporting Person's Rule 10b5-1 trading plan. This amendment reflects the exercise of stock options for 50,000 shares of common stock, which were the source of the shares sold.
F2: This transaction was executed pursuant to a Rule 10b5-1 trading plan in multiple trades at prices ranging from $36.1523 to $37.3689. The price reported above reflects the weighted average sales price. The reporting person hereby undertakes to provide upon request to the SEC staff, the Issuer or a security holder of the Issuer full information regarding the number of shares and prices at which the transaction was effected.
F3: The option vested 25% on September 23, 2021 and then in equal monthly installments over the following 3 years, subject to the Reporting Person's continued service to Issuer through each vesting date.
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| June 02, 2026 Filed Jun 3, 2026 23:48 UTC | CRESCENT BIOPHARMA, INC. CBIO · Entity 5255 | GrantStock Option (Right to Buy) · Derivative | 11,050 | $0.00 Strike: $17.01 | $0.00 |
DisclosureSEC source: 0001628280-26-040583 · wk-form4_1780530511.xml · derivative · entry 1 Violin Jonathan · CIK 0001730615 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 11,050 Underlying: Ordinary Shares · 11,050 shares Expires 2036-06-02 F1 · derivative.exercise_date: This option represents a right to purchase 11,050 of the Issuer's ordinary shares and vests in full on the earlier of (i) June 2, 2027 or (ii) the date of the Issuer's next annual meeting of shareholders, in each case, subject to the Reporting Person's continued service to the Issuer. Read SEC document |
| May 21, 2026 Filed May 22, 2026 20:30 UTC | Dianthus Therapeutics, Inc. /DE/ DNTH · Entity 1813 | GrantStock Option (Right to Buy) · Derivative | 6,090 | $0.00 Strike: $89.63 | $0.00 |
DisclosureSEC source: 0001730615-26-000003 · ownership.xml · derivative · entry 1 Violin Jonathan · CIK 0001730615 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 6,090 Underlying: Common Stock · 6,090 shares Expires 2036-05-21 F1 · derivative.exercise_date: The shares of common stock underlying this stock option award will vest in full on the date that is the earlier of (i) the first anniversary of the grant date or (ii) the Issuer's 2027 Annual Meeting of Stockholders, subject to the Reporting Person's continued service to the Issuer through the vesting date. Read SEC document |
| January 23, 2026 Filed Jan 23, 2026 16:37 UTC | Astria Therapeutics, Inc. ATXS · Entity 68888 | Disposition to issuerStock Option (Right to Buy) · Derivative | 26,550 | Not disclosed Strike: $5.79 | Not disclosed |
DisclosureSEC source: 0000905148-26-000324 · form4.xml · derivative · entry 6 Violin Jonathan · CIK 0001730615 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 26,550 shares Expires not disclosed F3 · price: At the Effective Time, each Issuer stock option for which the applicable exercise price was less than $13.00 (each, an "In-the-Money Option") that was outstanding immediately prior to the Effective Time became fully vested and exercisable and was canceled in exchange for the payment in cash equal to the product of (i) the total number of shares of common stock subject to such canceled In-the-Money Option immediately prior to the Effective Time and (ii) the excess of $13.00 over the exercise price per share subject to each such canceled In-the-Money Option, without interest. F3 · derivative.exercise_date: At the Effective Time, each Issuer stock option for which the applicable exercise price was less than $13.00 (each, an "In-the-Money Option") that was outstanding immediately prior to the Effective Time became fully vested and exercisable and was canceled in exchange for the payment in cash equal to the product of (i) the total number of shares of common stock subject to such canceled In-the-Money Option immediately prior to the Effective Time and (ii) the excess of $13.00 over the exercise price per share subject to each such canceled In-the-Money Option, without interest. F3 · derivative.expiration_date: At the Effective Time, each Issuer stock option for which the applicable exercise price was less than $13.00 (each, an "In-the-Money Option") that was outstanding immediately prior to the Effective Time became fully vested and exercisable and was canceled in exchange for the payment in cash equal to the product of (i) the total number of shares of common stock subject to such canceled In-the-Money Option immediately prior to the Effective Time and (ii) the excess of $13.00 over the exercise price per share subject to each such canceled In-the-Money Option, without interest. Read SEC document |
| January 23, 2026 Filed Jan 23, 2026 16:37 UTC | Astria Therapeutics, Inc. ATXS · Entity 68888 | Disposition to issuerStock Option (Right to Buy) · Derivative | 14,100 | Not disclosed Strike: $9.18 | Not disclosed |
DisclosureSEC source: 0000905148-26-000324 · form4.xml · derivative · entry 5 Violin Jonathan · CIK 0001730615 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 14,100 shares Expires not disclosed F3 · price: At the Effective Time, each Issuer stock option for which the applicable exercise price was less than $13.00 (each, an "In-the-Money Option") that was outstanding immediately prior to the Effective Time became fully vested and exercisable and was canceled in exchange for the payment in cash equal to the product of (i) the total number of shares of common stock subject to such canceled In-the-Money Option immediately prior to the Effective Time and (ii) the excess of $13.00 over the exercise price per share subject to each such canceled In-the-Money Option, without interest. F3 · derivative.exercise_date: At the Effective Time, each Issuer stock option for which the applicable exercise price was less than $13.00 (each, an "In-the-Money Option") that was outstanding immediately prior to the Effective Time became fully vested and exercisable and was canceled in exchange for the payment in cash equal to the product of (i) the total number of shares of common stock subject to such canceled In-the-Money Option immediately prior to the Effective Time and (ii) the excess of $13.00 over the exercise price per share subject to each such canceled In-the-Money Option, without interest. F3 · derivative.expiration_date: At the Effective Time, each Issuer stock option for which the applicable exercise price was less than $13.00 (each, an "In-the-Money Option") that was outstanding immediately prior to the Effective Time became fully vested and exercisable and was canceled in exchange for the payment in cash equal to the product of (i) the total number of shares of common stock subject to such canceled In-the-Money Option immediately prior to the Effective Time and (ii) the excess of $13.00 over the exercise price per share subject to each such canceled In-the-Money Option, without interest. Read SEC document |
| January 23, 2026 Filed Jan 23, 2026 16:37 UTC | Astria Therapeutics, Inc. ATXS · Entity 68888 | Disposition to issuerStock Option (Right to Buy) · Derivative | 14,100 | Not disclosed Strike: $11.35 | Not disclosed |
DisclosureSEC source: 0000905148-26-000324 · form4.xml · derivative · entry 4 Violin Jonathan · CIK 0001730615 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 14,100 shares Expires not disclosed F3 · price: At the Effective Time, each Issuer stock option for which the applicable exercise price was less than $13.00 (each, an "In-the-Money Option") that was outstanding immediately prior to the Effective Time became fully vested and exercisable and was canceled in exchange for the payment in cash equal to the product of (i) the total number of shares of common stock subject to such canceled In-the-Money Option immediately prior to the Effective Time and (ii) the excess of $13.00 over the exercise price per share subject to each such canceled In-the-Money Option, without interest. F3 · derivative.exercise_date: At the Effective Time, each Issuer stock option for which the applicable exercise price was less than $13.00 (each, an "In-the-Money Option") that was outstanding immediately prior to the Effective Time became fully vested and exercisable and was canceled in exchange for the payment in cash equal to the product of (i) the total number of shares of common stock subject to such canceled In-the-Money Option immediately prior to the Effective Time and (ii) the excess of $13.00 over the exercise price per share subject to each such canceled In-the-Money Option, without interest. F3 · derivative.expiration_date: At the Effective Time, each Issuer stock option for which the applicable exercise price was less than $13.00 (each, an "In-the-Money Option") that was outstanding immediately prior to the Effective Time became fully vested and exercisable and was canceled in exchange for the payment in cash equal to the product of (i) the total number of shares of common stock subject to such canceled In-the-Money Option immediately prior to the Effective Time and (ii) the excess of $13.00 over the exercise price per share subject to each such canceled In-the-Money Option, without interest. Read SEC document |
| January 23, 2026 Filed Jan 23, 2026 16:37 UTC | Astria Therapeutics, Inc. ATXS · Entity 68888 | Disposition to issuerStock Option (Right to Buy) · Derivative | 8,333 | Not disclosed Strike: $3.00 | Not disclosed |
DisclosureSEC source: 0000905148-26-000324 · form4.xml · derivative · entry 3 Violin Jonathan · CIK 0001730615 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 8,333 shares Expires not disclosed F3 · price: At the Effective Time, each Issuer stock option for which the applicable exercise price was less than $13.00 (each, an "In-the-Money Option") that was outstanding immediately prior to the Effective Time became fully vested and exercisable and was canceled in exchange for the payment in cash equal to the product of (i) the total number of shares of common stock subject to such canceled In-the-Money Option immediately prior to the Effective Time and (ii) the excess of $13.00 over the exercise price per share subject to each such canceled In-the-Money Option, without interest. F3 · derivative.exercise_date: At the Effective Time, each Issuer stock option for which the applicable exercise price was less than $13.00 (each, an "In-the-Money Option") that was outstanding immediately prior to the Effective Time became fully vested and exercisable and was canceled in exchange for the payment in cash equal to the product of (i) the total number of shares of common stock subject to such canceled In-the-Money Option immediately prior to the Effective Time and (ii) the excess of $13.00 over the exercise price per share subject to each such canceled In-the-Money Option, without interest. F3 · derivative.expiration_date: At the Effective Time, each Issuer stock option for which the applicable exercise price was less than $13.00 (each, an "In-the-Money Option") that was outstanding immediately prior to the Effective Time became fully vested and exercisable and was canceled in exchange for the payment in cash equal to the product of (i) the total number of shares of common stock subject to such canceled In-the-Money Option immediately prior to the Effective Time and (ii) the excess of $13.00 over the exercise price per share subject to each such canceled In-the-Money Option, without interest. Read SEC document |
| January 23, 2026 Filed Jan 23, 2026 16:37 UTC | Astria Therapeutics, Inc. ATXS · Entity 68888 | Disposition to issuerStock Option (Right to Buy) · Derivative | 14,166 | Not disclosed Strike: $12.24 | Not disclosed |
DisclosureSEC source: 0000905148-26-000324 · form4.xml · derivative · entry 2 Violin Jonathan · CIK 0001730615 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 14,166 shares Expires not disclosed F2 · derivative.exercise_price: These numbers have been adjusted to reflect the 1-for-6 reverse stock split the Issuer effected on August 19, 2021. F2 · shares: These numbers have been adjusted to reflect the 1-for-6 reverse stock split the Issuer effected on August 19, 2021. F3 · price: At the Effective Time, each Issuer stock option for which the applicable exercise price was less than $13.00 (each, an "In-the-Money Option") that was outstanding immediately prior to the Effective Time became fully vested and exercisable and was canceled in exchange for the payment in cash equal to the product of (i) the total number of shares of common stock subject to such canceled In-the-Money Option immediately prior to the Effective Time and (ii) the excess of $13.00 over the exercise price per share subject to each such canceled In-the-Money Option, without interest. F3 · derivative.exercise_date: At the Effective Time, each Issuer stock option for which the applicable exercise price was less than $13.00 (each, an "In-the-Money Option") that was outstanding immediately prior to the Effective Time became fully vested and exercisable and was canceled in exchange for the payment in cash equal to the product of (i) the total number of shares of common stock subject to such canceled In-the-Money Option immediately prior to the Effective Time and (ii) the excess of $13.00 over the exercise price per share subject to each such canceled In-the-Money Option, without interest. F3 · derivative.expiration_date: At the Effective Time, each Issuer stock option for which the applicable exercise price was less than $13.00 (each, an "In-the-Money Option") that was outstanding immediately prior to the Effective Time became fully vested and exercisable and was canceled in exchange for the payment in cash equal to the product of (i) the total number of shares of common stock subject to such canceled In-the-Money Option immediately prior to the Effective Time and (ii) the excess of $13.00 over the exercise price per share subject to each such canceled In-the-Money Option, without interest. F2 · derivative.underlying_shares: These numbers have been adjusted to reflect the 1-for-6 reverse stock split the Issuer effected on August 19, 2021. Read SEC document |
| January 23, 2026 Filed Jan 23, 2026 16:37 UTC | Astria Therapeutics, Inc. ATXS · Entity 68888 | Disposition to issuerCommon Stock | 263,321 | Not disclosed | Not disclosed |
DisclosureSEC source: 0000905148-26-000324 · form4.xml · nonDerivative · entry 1 Violin Jonathan · CIK 0001730615 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 0 F1 · price: Pursuant to an Agreement and Plan of Merger, dated as of October 14, 2025, by and among the Issuer, BioCryst Pharmaceuticals, Inc. ("BioCryst"), and Axel Merger Sub, Inc., a wholly-owned subsidiary of BioCryst, on January 23, 2026, Axel Merger Sub, Inc. merged with and into the Issuer, with the Issuer surviving and becoming a wholly-owned subsidiary of BioCryst (the "Merger"). At the effective time of the Merger (the "Effective Time"), each share of Issuer common stock, excluding shares held by the Issuer, BioCryst, or their wholly-owned subsidiaries or dissenting stockholders, that was issued and outstanding immediately prior to the Effective Time, was converted into the right to receive (i) 0.59 of a share of common stock of BioCryst and, if applicable, cash in lieu of fractional shares, and (ii) $8.55 in cash, without interest, subject to withholding taxes. Read SEC document |
| June 23, 2025 Filed Jun 23, 2025 22:46 UTC | CRESCENT BIOPHARMA, INC. CBIO · Entity 5255 | GrantStock Option (Right to Buy) · Derivative | 9,023 | $0.00 Strike: $15.30 | $0.00 |
DisclosureSEC source: 0001104659-25-061818 · tm2518376-15_4seq1.xml · derivative · entry 1 Violin Jonathan · CIK 0001730615 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 9,023 Underlying: Ordinary Shares · 9,023 shares Expires 2035-06-23 F1 · derivative.exercise_date: This option represents a right to purchase shares of the Issuer's ordinary shares and vests in full on the earlier of (i) June 23, 2026 or (ii) the date of the Issuer's next annual meeting of shareholders, in each case, subject to the Reporting Person's continued service to the Issuer. Read SEC document |
| June 11, 2025 Filed Jun 12, 2025 19:11 UTC | Astria Therapeutics, Inc. ATXS · Entity 68888 | GrantStock Option (Right to Buy) · Derivative | 26,550 | $0.00 Strike: $5.79 | $0.00 |
DisclosureSEC source: 0001104659-25-059031 · tm2517800-3_4seq1.xml · derivative · entry 1 Violin Jonathan · CIK 0001730615 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 26,550 Underlying: Common Stock · 26,550 shares Expires 2035-06-10 F1 · derivative.exercise_date: This option was granted on June 11, 2025 and will vest in its entirety on the one-year anniversary of the grant date, subject to the director's continued service. Read SEC document |
| May 22, 2025 Filed May 22, 2025 20:44 UTC | Dianthus Therapeutics, Inc. /DE/ DNTH · Entity 1813 | GrantStock Option (Right to Buy) · Derivative | 12,500 | $0.00 Strike: $18.36 | $0.00 |
DisclosureSEC source: 0000950170-25-076412 · ownership.xml · derivative · entry 1 Violin Jonathan · CIK 0001730615 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 12,500 Underlying: Common Stock · 12,500 shares Expires 2035-05-22 F1 · derivative.exercise_date: The shares of common stock underlying this stock option award will vest in full on the date that is the earlier of (i) the first anniversary of the grant date or (ii) the Issuer's 2026 Annual Meeting of Stockholders, subject to the Reporting Person's continued service to the Issuer through the vesting date. Read SEC document |
| June 05, 2024 Filed Jun 6, 2024 16:06 UTC | Astria Therapeutics, Inc. ATXS · Entity 68888 | GrantStock Option (Right to Buy) · Derivative | 14,100 | $0.00 Strike: $9.18 | $0.00 |
DisclosureSEC source: 0001104659-24-069074 · tm2416582-5_4seq1.xml · derivative · entry 1 Violin Jonathan · CIK 0001730615 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 14,100 Underlying: Common Stock · 14,100 shares Expires 2034-06-04 F1 · derivative.exercise_date: This option was granted on June 5, 2024 and will vest in its entirety on the one-year anniversary of the grant date, subject to the director's continued service. Read SEC document |
| May 23, 2024 Filed May 29, 2024 00:02 UTC | Dianthus Therapeutics, Inc. /DE/ DNTH · Entity 1813 | GrantStock Option (Right to Buy) · Derivative | 11,000 | $0.00 Strike: $21.77 | $0.00 |
DisclosureSEC source: 0000950170-24-065560 · ownership.xml · derivative · entry 1 Violin Jonathan · CIK 0001730615 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 11,000 Underlying: Common Stock · 11,000 shares Expires 2034-05-22 F1 · derivative.exercise_date: The shares of common stock underlying this stock option award will vest in full on the date that is the earlier of (i) the first anniversary of the grant date or (ii) the Issuer's 2025 Annual Meeting of Stockholders, subject to the Reporting Person's continued service to the Issuer through the vesting date. Read SEC document |
| September 11, 2023 Filed Sep 14, 2023 01:25 UTC | Dianthus Therapeutics, Inc. /DE/ DNTH · Entity 1813 | GrantStock Option (Right to Buy) · Derivative | 6,500 | $0.00 Strike: $11.20 | $0.00 |
DisclosureSEC source: 0000899243-23-018869 · doc4.xml · derivative · entry 1 Violin Jonathan · CIK 0001730615 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 6,500 Underlying: Common Stock · 6,500 shares Expires 2033-09-10 F1 · derivative.exercise_date: This option represents a right to purchase a total of 6,500 shares of the Issuer's common stock, which will vest in full on the date that is the earlier of (i) the Issuer's 2024 Annual Meeting of Stockholders and (ii) September 11, 2024, subject to the Reporting Person's continued service to the Issuer. Read SEC document |
| June 02, 2023 Filed Jun 6, 2023 08:06 UTC | Astria Therapeutics, Inc. ATXS · Entity 68888 | GrantStock Option (Right to Buy) · Derivative | 14,100 | $0.00 Strike: $11.35 | $0.00 |
DisclosureSEC source: 0001104659-23-068340 · tm2317752-7_4seq1.xml · derivative · entry 1 Violin Jonathan · CIK 0001730615 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 14,100 Underlying: Common Stock · 14,100 shares Expires 2033-06-01 F1 · derivative.exercise_date: This option was granted on June 2, 2023 and will vest in its entirety on the one-year anniversary of the grant date, subject to the director's continued service. Read SEC document |
| February 02, 2023 Filed Feb 3, 2023 23:12 UTC | Viridian Therapeutics, Inc.\DE VRDN · Entity 4316 | SaleCommon Stock | 50,000 | $36.80 | $1,840,000.00 |
DisclosureSEC source: 0000899243-23-003921 · doc4.xml · nonDerivative · entry 1 Violin Jonathan · CIK 0001730615 · Director · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 430,905 F1 · price: This transaction was executed pursuant to a Rule 10b5-1 trading plan in multiple trades at prices ranging from $36.1523 to $37.3689. The price reported above reflects the weighted average sales price. The reporting person hereby undertakes to provide upon request to the SEC staff, the Issuer or a security holder of the Issuer full information regarding the number of shares and prices at which the transaction was effected. Read SEC document |
| February 02, 2023 Filed Feb 7, 2023 23:35 UTC Amendment | Viridian Therapeutics, Inc.\DE VRDN · Entity 4316 | Exercise / conversionStock Option (Right to Buy) · Derivative | 50,000 | $0.00 Strike: $0.15 | $0.00 |
DisclosureSEC source: 0000899243-23-004233 · doc4a.xml · derivative · entry 3 Violin Jonathan · CIK 0001730615 · Director · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 239,205 Underlying: Common Stock · 50,000 shares Expires 2030-09-23 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F3 · derivative.exercise_date: The option vested 25% on September 23, 2021 and then in equal monthly installments over the following 3 years, subject to the Reporting Person's continued service to Issuer through each vesting date. Read SEC document |
| February 02, 2023 Filed Feb 7, 2023 23:35 UTC Amendment | Viridian Therapeutics, Inc.\DE VRDN · Entity 4316 | SaleCommon Stock | 50,000 | $36.80 | $1,840,000.00 |
DisclosureSEC source: 0000899243-23-004233 · doc4a.xml · nonDerivative · entry 2 Violin Jonathan · CIK 0001730615 · Director · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 480,905 F2 · price: This transaction was executed pursuant to a Rule 10b5-1 trading plan in multiple trades at prices ranging from $36.1523 to $37.3689. The price reported above reflects the weighted average sales price. The reporting person hereby undertakes to provide upon request to the SEC staff, the Issuer or a security holder of the Issuer full information regarding the number of shares and prices at which the transaction was effected. Read SEC document |
| February 02, 2023 Filed Feb 7, 2023 23:35 UTC Amendment | Viridian Therapeutics, Inc.\DE VRDN · Entity 4316 | Exercise / conversionCommon Stock | 50,000 | $0.15 | $7,500.00 |
DisclosureSEC source: 0000899243-23-004233 · doc4a.xml · nonDerivative · entry 1 Violin Jonathan · CIK 0001730615 · Director · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 530,905 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: Due to a broker error, the Form 4 filed by the Reporting Person on February 3, 2023 incorrectly reported the source of shares sold on February 2, 2023 pursuant to the Reporting Person's Rule 10b5-1 trading plan. This amendment reflects the exercise of stock options for 50,000 shares of common stock, which were the source of the shares sold. Read SEC document |
| June 09, 2022 Filed Jun 9, 2022 17:59 UTC | Astria Therapeutics, Inc. ATXS · Entity 68888 | GrantStock Option (right to buy) · Derivative | 8,333 | $0.00 Strike: $2.99 | $0.00 |
DisclosureSEC source: 0001104659-22-069758 · tm2218033-5_4seq1.xml · derivative · entry 1 Violin Jonathan · CIK 0001730615 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 8,333 Underlying: Common Stock · 8,333 shares Expires 2032-06-08 F1 · derivative.exercise_date: This option was granted on June 9, 2022 and will vest in its entirety on the one-year anniversary of the grant date, subject to the director's continued service. Read SEC document |
| June 09, 2022 Filed Jun 21, 2022 08:33 UTC Amendment | Astria Therapeutics, Inc. ATXS · Entity 68888 | GrantStock Option (right to buy) · Derivative | 8,333 | $0.00 Strike: $3.00 | $0.00 |
DisclosureSEC source: 0001104659-22-072752 · tm2218796-5_4aseq1.xml · derivative · entry 1 Violin Jonathan · CIK 0001730615 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 8,333 Underlying: Common Stock · 8,333 shares Expires 2032-06-08 F1 · derivative.exercise_price: This amendment is being made to show the correct price of $3.00. An incorrect price of $2.99 was previously reported. F2 · derivative.exercise_date: This option was granted on June 9, 2022 and will vest in its entirety on the one-year anniversary of the grant date, subject to the director's continued service. Read SEC document |
| June 01, 2022 Filed Jun 2, 2022 21:29 UTC | Viridian Therapeutics, Inc.\DE VRDN · Entity 4316 | SaleCommon Stock | 30,000 | $12.20 | $366,000.00 |
DisclosureSEC source: 0000899243-22-020717 · doc4.xml · nonDerivative · entry 1 Violin Jonathan · CIK 0001730615 · Director · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 480,905 F1 · price: This transaction was executed pursuant to a Rule 10b5-1 trading plan in multiple trades at prices ranging from $12.01 to $12.61. The price reported above reflects the weighted average sales price. The reporting person hereby undertakes to provide upon request to the SEC staff, the Issuer or a security holder of the Issuer full information regarding the number of shares and prices at which the transaction was effected. Read SEC document |
| May 02, 2022 Filed May 4, 2022 21:23 UTC | Viridian Therapeutics, Inc.\DE VRDN · Entity 4316 | SaleCommon Stock | 30,000 | $13.04 | $391,200.00 |
DisclosureSEC source: 0000899243-22-016657 · doc4.xml · nonDerivative · entry 1 Violin Jonathan · CIK 0001730615 · Director · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 510,905 F1 · price: This transaction was executed pursuant to a Rule 10b5-1 trading plan in multiple trades at prices ranging from $12.69 to $13.75. The price reported above reflects the weighted average sales price. The reporting person hereby undertakes to provide upon request to the SEC staff, the Issuer or a security holder of the Issuer full information regarding the number of shares and prices at which the transaction was effected. Read SEC document |
| April 04, 2022 Filed Apr 5, 2022 22:09 UTC | Viridian Therapeutics, Inc.\DE VRDN · Entity 4316 | SaleCommon Stock | 3,600 | $18.93 | $68,148.00 |
DisclosureSEC source: 0000899243-22-013858 · doc4.xml · nonDerivative · entry 2 Violin Jonathan · CIK 0001730615 · Director · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 540,905 F2 · price: This transaction was executed pursuant to a Rule 10b5-1 trading plan in multiple trades at prices ranging from $18.64 to $19.16. The price reported above reflects the weighted average sales price. The reporting person hereby undertakes to provide upon request to the SEC staff, the Issuer or a security holder of the Issuer full information regarding the number of shares and prices at which the transaction was effected. Read SEC document |
| April 01, 2022 Filed Apr 5, 2022 22:09 UTC | Viridian Therapeutics, Inc.\DE VRDN · Entity 4316 | SaleCommon Stock | 26,400 | $18.92 | $499,488.00 |
DisclosureSEC source: 0000899243-22-013858 · doc4.xml · nonDerivative · entry 1 Violin Jonathan · CIK 0001730615 · Director · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 544,505 F1 · price: This transaction was executed pursuant to a Rule 10b5-1 trading plan in multiple trades at prices ranging from $18.34 to $19.43. The price reported above reflects the weighted average sales price. The reporting person hereby undertakes to provide upon request to the SEC staff, the Issuer or a security holder of the Issuer full information regarding the number of shares and prices at which the transaction was effected. Read SEC document |
| March 02, 2022 Filed Mar 3, 2022 21:48 UTC | Viridian Therapeutics, Inc.\DE VRDN · Entity 4316 | SaleCommon Stock | 11,106 | $17.36 | $192,800.16 |
DisclosureSEC source: 0000899243-22-009096 · doc4.xml · nonDerivative · entry 2 Violin Jonathan · CIK 0001730615 · Director · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 570,905 F2 · price: This transaction was executed pursuant to a Rule 10b5-1 trading plan in multiple trades at prices ranging from $17.05 to $18.06. The price reported above reflects the weighted average sales price. The reporting person hereby undertakes to provide upon request to the SEC staff, the Issuer or a security holder of the Issuer full information regarding the number of shares and prices at which the transaction was effected. Read SEC document |
| March 01, 2022 Filed Mar 3, 2022 21:48 UTC | Viridian Therapeutics, Inc.\DE VRDN · Entity 4316 | SaleCommon Stock | 18,894 | $17.82 | $336,691.08 |
DisclosureSEC source: 0000899243-22-009096 · doc4.xml · nonDerivative · entry 1 Violin Jonathan · CIK 0001730615 · Director · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 582,011 F1 · price: This transaction was executed pursuant to a Rule 10b5-1 trading plan in multiple trades at prices ranging from $17.62 to $18.30. The price reported above reflects the weighted average sales price. The reporting person hereby undertakes to provide upon request to the SEC staff, the Issuer or a security holder of the Issuer full information regarding the number of shares and prices at which the transaction was effected. Read SEC document |
| February 03, 2022 Filed Feb 3, 2022 23:11 UTC | Viridian Therapeutics, Inc.\DE VRDN · Entity 4316 | SaleCommon Stock | 909 | $19.16 | $17,416.44 |
DisclosureSEC source: 0000899243-22-004665 · doc4.xml · nonDerivative · entry 3 Violin Jonathan · CIK 0001730615 · Director · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 600,905 F3 · price: This transaction was executed pursuant to a Rule 10b5-1 trading plan in multiple trades at prices ranging from $18.04 to $19.66. The price reported above reflects the weighted average sales price. The reporting person hereby undertakes to provide upon request to the SEC staff, the Issuer or a security holder of the Issuer full information regarding the number of shares and prices at which the transaction was effected. Read SEC document |
| February 02, 2022 Filed Feb 3, 2022 23:11 UTC | Viridian Therapeutics, Inc.\DE VRDN · Entity 4316 | GrantStock Option (Right to Buy) · Derivative | 280,000 | $0.00 Strike: $18.51 | $0.00 |
DisclosureSEC source: 0000899243-22-004665 · doc4.xml · derivative · entry 4 Violin Jonathan · CIK 0001730615 · Director · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 280,000 Underlying: Common Stock · 280,000 shares Expires 2032-02-02 F4 · derivative.exercise_date: The option vests in equal monthly installments through February 2, 2026, subject to the Reporting Person's continued service to Issuer through each vesting date. Read SEC document |
| February 02, 2022 Filed Feb 3, 2022 23:11 UTC | Viridian Therapeutics, Inc.\DE VRDN · Entity 4316 | SaleCommon Stock | 12,340 | $18.47 | $227,919.80 |
DisclosureSEC source: 0000899243-22-004665 · doc4.xml · nonDerivative · entry 2 Violin Jonathan · CIK 0001730615 · Director · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 601,814 F2 · price: This transaction was executed pursuant to a Rule 10b5-1 trading plan in multiple trades at prices ranging from $18.32 to $19.49. The price reported above reflects the weighted average sales price. The reporting person hereby undertakes to provide upon request to the SEC staff, the Issuer or a security holder of the Issuer full information regarding the number of shares and prices at which the transaction was effected. Read SEC document |
| February 01, 2022 Filed Feb 3, 2022 23:11 UTC | Viridian Therapeutics, Inc.\DE VRDN · Entity 4316 | SaleCommon Stock | 16,751 | $19.55 | $327,482.05 |
DisclosureSEC source: 0000899243-22-004665 · doc4.xml · nonDerivative · entry 1 Violin Jonathan · CIK 0001730615 · Director · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 614,154 F1 · price: This transaction was executed pursuant to a Rule 10b5-1 trading plan in multiple trades at prices ranging from $18.90 to $20.23. The price reported above reflects the weighted average sales price. The reporting person hereby undertakes to provide upon request to the SEC staff, the Issuer or a security holder of the Issuer full information regarding the number of shares and prices at which the transaction was effected. Read SEC document |
| December 08, 2021 Filed Dec 10, 2021 23:08 UTC | Viridian Therapeutics, Inc.\DE VRDN · Entity 4316 | ConversionSeries A Non-Voting Convertible Preferred Stock · Derivative | 9,413 | $0.00 | $0.00 |
DisclosureSEC source: 0000899243-21-047801 · doc4.xml · derivative · entry 2 Violin Jonathan · CIK 0001730615 · Director · See Remarks 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 627,564 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: Each share of Series A Non-Voting Convertible Preferred Stock is convertible into shares of Common Stock at any time at the option of the holder thereof, into 66.67 shares of Common Stock, subject to certain limitations. F1 · derivative.exercise_date: Each share of Series A Non-Voting Convertible Preferred Stock is convertible into shares of Common Stock at any time at the option of the holder thereof, into 66.67 shares of Common Stock, subject to certain limitations. F1 · derivative.expiration_date: Each share of Series A Non-Voting Convertible Preferred Stock is convertible into shares of Common Stock at any time at the option of the holder thereof, into 66.67 shares of Common Stock, subject to certain limitations. Read SEC document |
| December 08, 2021 Filed Dec 10, 2021 23:08 UTC | Viridian Therapeutics, Inc.\DE VRDN · Entity 4316 | ConversionCommon Stock | 627,564 | $0.00 | $0.00 |
DisclosureSEC source: 0000899243-21-047801 · doc4.xml · nonDerivative · entry 1 Violin Jonathan · CIK 0001730615 · Director · See Remarks 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 630,905 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| September 20, 2021 Filed Sep 22, 2021 17:00 UTC | Astria Therapeutics, Inc. ATXS · Entity 68888 | OtherCommon Stock | 263,321 | $0.00 | $0.00 |
DisclosureSEC source: 0001104659-21-118359 · tm2128174-1_4seq1.xml · nonDerivative · entry 2 Violin Jonathan · CIK 0001730615 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 263,321 F1 · kind: On September 20, 2021, Lazarus Life Sciences I, LLC ("Lazarus"), a limited liability company in which the Reporting Person holds a profits interest, distributed all of its shares of common stock of the Issuer to its beneficial owners, including 263,321 shares of common stock to the Reporting Person. The Reporting Person disclaims beneficial ownership of the securities held by Lazarus, except to the extent of his pecuniary interest therein. All share numbers herein give effect to the one-for-six reverse stock split effected by the Issuer on August 19, 2021. Read SEC document |
| September 20, 2021 Filed Sep 22, 2021 17:00 UTC | Astria Therapeutics, Inc. ATXS · Entity 68888 | OtherCommon Stock | 263,321 | $0.00 | $0.00 |
DisclosureSEC source: 0001104659-21-118359 · tm2128174-1_4seq1.xml · nonDerivative · entry 1 Violin Jonathan · CIK 0001730615 · Director 10b5-1 filing: Not disclosed Ownership: Indirect · By Lazarus Life Sciences I, LLC Disclosed balance after: 0 F1 · kind: On September 20, 2021, Lazarus Life Sciences I, LLC ("Lazarus"), a limited liability company in which the Reporting Person holds a profits interest, distributed all of its shares of common stock of the Issuer to its beneficial owners, including 263,321 shares of common stock to the Reporting Person. The Reporting Person disclaims beneficial ownership of the securities held by Lazarus, except to the extent of his pecuniary interest therein. All share numbers herein give effect to the one-for-six reverse stock split effected by the Issuer on August 19, 2021. F1 · ownership.nature: On September 20, 2021, Lazarus Life Sciences I, LLC ("Lazarus"), a limited liability company in which the Reporting Person holds a profits interest, distributed all of its shares of common stock of the Issuer to its beneficial owners, including 263,321 shares of common stock to the Reporting Person. The Reporting Person disclaims beneficial ownership of the securities held by Lazarus, except to the extent of his pecuniary interest therein. All share numbers herein give effect to the one-for-six reverse stock split effected by the Issuer on August 19, 2021. Read SEC document |
| June 02, 2021 Filed Jun 2, 2021 19:17 UTC | Astria Therapeutics, Inc. CATB · Entity 68888 | GrantStock Option (right to buy) · Derivative | 85,000 | $0.00 Strike: $2.04 | $0.00 |
DisclosureSEC source: 0001104659-21-075909 · tm2118270-9_4seq1.xml · derivative · entry 1 Violin Jonathan · CIK 0001730615 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 85,000 Underlying: Common Stock · 85,000 shares Expires 2031-06-01 F1 · derivative.exercise_date: This option was granted on June 2, 2021 and is schedule to vest in equal annual installments over a three-year period from the date of grant, subject to the director's continued service. Read SEC document |
| January 28, 2021 Filed Feb 1, 2021 21:56 UTC | Astria Therapeutics, Inc. CATB · Entity 68888 | GrantStock Option (Right to Buy) · Derivative | 15,000 | $0.00 Strike: $2.43 | $0.00 |
DisclosureSEC source: 0000899243-21-004013 · doc4.xml · derivative · entry 1 Violin Jonathan · CIK 0001730615 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 15,000 Underlying: Common Stock · 15,000 shares Expires 2031-01-27 F1 · derivative.exercise_date: This option was granted on January 28, 2021 and is scheduled to vest as to one-third of the common stock underlying the option on each anniversary of the grant date until the third anniversary of the grant date. Read SEC document |
| January 18, 2021 Filed Jan 20, 2021 20:48 UTC | Viridian Therapeutics, Inc.\DE VRDN · Entity 4316 | GrantEmployee Stock Option (right to buy) · Derivative | 800,075 | $0.00 Strike: $23.03 | $0.00 |
DisclosureSEC source: 0000899243-21-002484 · doc4.xml · derivative · entry 1 Violin Jonathan · CIK 0001730615 · Director · CEO and President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 800,075 Underlying: Common Stock · 800,075 shares Expires 2031-01-17 F1 · derivative.exercise_date: The option vests in equal monthly installments over the following 4 years, subject to the Reporting Person's continued service to Issuer through each vesting date. Read SEC document |
| October 27, 2020 Filed Oct 30, 2020 22:57 UTC | Viridian Therapeutics, Inc.\DE MGEN · Entity 4316 | OtherSeries A Non-Voting Convertible Preferred Stock · Derivative | 9,413 | Not disclosed | Not disclosed |
DisclosureSEC source: 0000899243-20-029996 · doc4.xml · derivative · entry 3 Violin Jonathan · CIK 0001730615 · President and COO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 9,413 Underlying: Common Stock · 9,413,000 shares Expires not disclosed F4 · derivative.exercise_price: Following stockholder approval of the conversion of Series A Non-Voting Convertible Preferred Stock into shares of Common Stock, each share of Series A Non-Voting Convertible Preferred Stock is convertible into shares of Common Stock at any time at the option of the holder thereof, into 1,000 shares of Common Stock, subject to certain limitations. F1 · kind: On October 27, 2020, Issuer completed its merger with Viridian Therapeutics, Inc. ("Merger"), in accordance with the terms of the Agreement and Plan of Merger, dated October 27, 2020. In connection with the Merger, the Reporting Person received such shares in exchange for 857,000 shares of Viridian Therapeutics, Inc. common stock. F1 · price: On October 27, 2020, Issuer completed its merger with Viridian Therapeutics, Inc. ("Merger"), in accordance with the terms of the Agreement and Plan of Merger, dated October 27, 2020. In connection with the Merger, the Reporting Person received such shares in exchange for 857,000 shares of Viridian Therapeutics, Inc. common stock. F4 · derivative.exercise_date: Following stockholder approval of the conversion of Series A Non-Voting Convertible Preferred Stock into shares of Common Stock, each share of Series A Non-Voting Convertible Preferred Stock is convertible into shares of Common Stock at any time at the option of the holder thereof, into 1,000 shares of Common Stock, subject to certain limitations. F4 · derivative.expiration_date: Following stockholder approval of the conversion of Series A Non-Voting Convertible Preferred Stock into shares of Common Stock, each share of Series A Non-Voting Convertible Preferred Stock is convertible into shares of Common Stock at any time at the option of the holder thereof, into 1,000 shares of Common Stock, subject to certain limitations. Read SEC document |
| October 27, 2020 Filed Oct 30, 2020 22:57 UTC | Viridian Therapeutics, Inc.\DE MGEN · Entity 4316 | OtherEmployee Stock Option (Right to Buy) · Derivative | 4,338,079 | Not disclosed Strike: $0.01 | Not disclosed |
DisclosureSEC source: 0000899243-20-029996 · doc4.xml · derivative · entry 2 Violin Jonathan · CIK 0001730615 · President and COO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 4,338,079 Underlying: Common Stock · 4,338,079 shares Expires 2030-09-23 F1 · kind: On October 27, 2020, Issuer completed its merger with Viridian Therapeutics, Inc. ("Merger"), in accordance with the terms of the Agreement and Plan of Merger, dated October 27, 2020. In connection with the Merger, the Reporting Person received such shares in exchange for 857,000 shares of Viridian Therapeutics, Inc. common stock. F3 · price: Received in the Merger in exchange for an employee stock option to acquire 392,857 shares of Viridian Therapeutics, Inc. common stock for $0.03 per share. F2 · derivative.exercise_date: The option vests 25% on September 23, 2021 and then in equal monthly installments over the following 3 years, subject to the Reporting Person's continued service to Issuer through each vesting date. Read SEC document |
| October 27, 2020 Filed Oct 30, 2020 22:57 UTC | Viridian Therapeutics, Inc.\DE MGEN · Entity 4316 | OtherCommon Stock | 50,124 | Not disclosed | Not disclosed |
DisclosureSEC source: 0000899243-20-029996 · doc4.xml · nonDerivative · entry 1 Violin Jonathan · CIK 0001730615 · President and COO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 50,124 F1 · kind: On October 27, 2020, Issuer completed its merger with Viridian Therapeutics, Inc. ("Merger"), in accordance with the terms of the Agreement and Plan of Merger, dated October 27, 2020. In connection with the Merger, the Reporting Person received such shares in exchange for 857,000 shares of Viridian Therapeutics, Inc. common stock. F1 · price: On October 27, 2020, Issuer completed its merger with Viridian Therapeutics, Inc. ("Merger"), in accordance with the terms of the Agreement and Plan of Merger, dated October 27, 2020. In connection with the Merger, the Reporting Person received such shares in exchange for 857,000 shares of Viridian Therapeutics, Inc. common stock. Read SEC document |
| February 28, 2018 Filed Mar 2, 2018 22:25 UTC | TREVENA INC TRVN · Entity 85383 | GrantEmployee Stock Option (Right to Buy) · Derivative | 65,000 | $0.00 Strike: $1.79 | $0.00 |
DisclosureSEC source: 0001209191-18-015856 · doc4.xml · derivative · entry 2 Violin Jonathan · CIK 0001730615 · SVP-Scientific Affairs & IR 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 65,000 Underlying: Common Stock · 65,000 shares Expires 2028-02-28 F2 · derivative.exercise_date: The option shall vest and become exercisable on an annual basis (every twelve months) from the Transaction Date listed above, with respect to one-half of the total number of shares subject to the option, in each case subject to the reporting person's Continuous Service (as defined in the 2013 Equity Incentive Plan, as amended) as of each such vesting date. Read SEC document |
| February 28, 2018 Filed Mar 2, 2018 22:25 UTC | TREVENA INC TRVN · Entity 85383 | GrantEmployee Stock Option (Right to Buy) · Derivative | 75,000 | $0.00 Strike: $1.79 | $0.00 |
DisclosureSEC source: 0001209191-18-015856 · doc4.xml · derivative · entry 1 Violin Jonathan · CIK 0001730615 · SVP-Scientific Affairs & IR 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 75,000 Underlying: Common Stock · 75,000 shares Expires 2028-02-28 F1 · derivative.exercise_date: The option shall vest and become exercisable with respect to one-sixteenth of the total number of shares subject to the option on a quarterly basis (every three months) from the Transaction Date listed above, subject to the reporting person's Continuous Service (as defined in the Trevena, Inc. 2013 Equity Incentive Plan, as amended) as of each such vesting date. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.